Inhibitor Therapeutics, Inc.
INTI
$0.049
-$0.0006-1.21%
OTC PK
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 3.74M | 4.32M | 5.61M | 6.38M | 7.10M |
Total Receivables | -- | -- | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 92.00K | 99.10K | 87.80K | 73.10K | 74.60K |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 3.83M | 4.42M | 5.69M | 6.45M | 7.17M |
|
|||||
Total Current Assets | 3.83M | 4.42M | 5.69M | 6.45M | 7.17M |
Net Property, Plant & Equipment | 77.70K | 84.30K | -- | -- | -- |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | -- | -- | -- | -- | -- |
Total Assets | 3.91M | 4.51M | 5.69M | 6.45M | 7.17M |
|
|||||
Total Accounts Payable | 106.20K | 36.70K | 15.90K | 1.70K | 18.80K |
Total Accrued Expenses | 7.70K | 32.00K | 693.70K | 42.90K | 16.70K |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 26.00K | 26.00K | -- | -- | -- |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 140.00K | 94.70K | 709.60K | 44.60K | 35.50K |
|
|||||
Total Current Liabilities | 140.00K | 94.70K | 709.60K | 44.60K | 35.50K |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 52.10K | 58.40K | -- | -- | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
Total Liabilities | 3.19M | 3.15M | 3.71M | 3.04M | 3.04M |
|
|||||
Common Stock & APIC | 54.13M | 54.10M | 54.10M | 54.10M | 54.10M |
Retained Earnings | -53.41M | -52.75M | -52.12M | -50.70M | -49.97M |
Treasury Stock & Other | -- | -- | -- | -- | -- |
Total Common Equity | 715.60K | 1.35M | 1.99M | 3.41M | 4.14M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 715.60K | 1.35M | 1.99M | 3.41M | 4.14M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 715.60K | 1.35M | 1.99M | 3.41M | 4.14M |
|